

# ALEXEY TARASOV

*Admitted to U.S. Supreme Court,  
Courts of Appeals for the  
Second, Fourth, Fifth, Seventh,  
Eighth, Ninth & Tenth Circuits,  
Southern District of Texas,  
District of Columbia,  
Southern & Eastern  
Districts of New York,  
Western District of Oklahoma*

attorney and counselor at law

5211 Reading Road  
Rosenberg, Texas 77471  
330 W. Gray Street, suite 208  
Norman, Oklahoma 73069

*licensed in Texas,  
Oklahoma, New York*

*telephone: 832.623.6250  
fax: 832.558.3540  
alexey@tarasovlaw.com*

May 2, 2023

## **Via Electronic Transmission**

OTC Markets Group Inc.  
300 Vesey Street, 12th Floor  
New York, NY 10282

Subject: Correspondence Regarding Current Information – RAFA

Dear Sir/Madam:

I have been engaged by Rafarma Pharmaceuticals, Inc. (“RAFA”), a Wyoming Corporation, whose primary office is located at 12465 South Street STE 240, Draper, UT 84020 (hereinafter referred to as the “Issuer”), specifically to provide this letter. Only OTC Markets Group is authorized to rely on this letter and use it to determine if adequate current information has been made publicly available on its website, as per Rule 144(c)(2) of the Securities Act of 1933. OTC Markets Group is granted unrestricted permission and rights to publish this letter through the OTC Disclosure & News Service for public access.

I am a U.S. resident and hold licenses to practice law in Texas, Oklahoma, and New York. I have not been suspended or barred from practicing law in any state or jurisdiction, including the Securities and Exchange Commission (“SEC”), nor have I faced any civil or criminal charges. My role as independent counsel is solely to review the current information provided by the issuer. I do not possess any beneficial ownership in the Issuer’s securities. I have not received, nor do I have an agreement to receive in the future, shares of the Issuer’s stock as payment for services.

To prepare this letter, I have reviewed pertinent corporate records and other documents, as well as addressed any legal questions I deemed necessary or relevant. The documents I have examined (“Information”) encompass, but are not limited to:

| OTC Publish Date | OTC Disclosures Title                            | Period End Date |
|------------------|--|-----------------|
| 04/26/2023       | Annual Report – Annual Report – RAFA Report 2022 | 12/31/2022      |
| 11/14/2022       | Quarterly Report – Quarterly Report              | 09/30/2022      |
| 11/14/2022       | Quarterly Report – Q3 Financials – RAFA          | 09/30/2022      |
| 09/06/2022       | Quarterly Report – Quarterly Report – Finance    | 06/30/2022      |
| 09/06/2022       | Quarterly Report – Quarterly Report              | 06/30/2022      |
| 05/18/2022       | Quarterly Report – Q1 Financials – RAFA          | 03/31/2022      |
| 05/18/2022       | Quarterly Report – Quarterly Report              | 03/31/2022      |

In regard to factual matters, I have depended on information gathered from public officials, officers, and directors of the Issuer, and other sources, which are considered trustworthy. When examining the Information, I have assumed that:

1. All statements and representations within the Information were accurate and reliable;
2. All signatures within were authentic;
3. All documents provided to me were true copies; and
4. All individuals who signed documents possessed the legal capacity to do so.


Upon conducting the aforementioned review and considering other matters detailed herein, I am of the opinion that the Information (i) represents “adequate current public information” about the Securities and the Issuer; (ii) has been made publicly accessible as per Rule 144(c)(2) under the Securities Act; (iii) contains all information a broker-dealer would need to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 of the Securities Exchange Act of 1934 (the “Exchange Act”); (iv) adheres to the form requirements of the OTC Markets Group’s Pink Basic Disclosure Guidelines; and (v) has been submitted through the OTC Disclosure & News Service.

Raivo Unt, the President, who I have personally communicated with, was responsible for preparing the Disclosure Statement included in the Information. The Issuer’s transfer agent is Action Stock Transfer, which is registered with the Securities and Exchange Commission. I relied on information provided by Action Stock Transfer to verify the number of outstanding shares mentioned in the Information.

To the best of my knowledge, after inquiring with the Issuer’s management and directors, neither the Issuer, any 5% holder, nor counsel, is presently under investigation by any federal or state regulatory authority for violations of federal or state securities laws.

The Issuer is not classified as a “shell company” according to Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. No party other than the OTC Markets Group may rely on this letter; however, the OTC Markets Group has unrestricted permission and rights to publish the letter through the OTC Disclosure & News Service for public access. This letter pertains solely to the referenced report periods and is not applicable to any other period.

Respectfully,



Alexey V. Tarasov, Esq.